{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:54:50Z","timestamp":1773111290910,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.clinthera.2014.09.016","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T03:15:44Z","timestamp":1414120544000},"page":"1566-1573.e3","source":"Crossref","is-referenced-by-count":8,"title":["Reviewing a Clinical Decision Aid for the Selection of Anticoagulation Treatment in Patients With Nonvalvular Atrial Fibrillation: Applications in a US Managed Care Health Plan Database"],"prefix":"10.1016","volume":"36","author":[{"given":"Steven B.","family":"Deitelzweig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Swindle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinara","family":"Makenbaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.09.016_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1477-9560-11-27","article-title":"Practical management of patients on apixaban: a consensus guide","volume":"11","author":"Ward","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.clinthera.2014.09.016_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and cons of new oral anticoagulants. Hematology \/ The Education Program of the American Society of Hematology","author":"Bauer","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2014.09.016_bib3","first-page":"640723","article-title":"rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of subgroups","author":"Gomez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.clinthera.2014.09.016_bib4","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/eurheartj\/ehs167","article-title":"A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation","volume":"33","author":"LaHaye","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.09.016_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2014.09.016_bib6","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2014.09.016_bib7","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2014.09.016_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2014.09.016_bib9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in \u2019real world\u2019 patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","author":"Olesen","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.09.016_bib10","series-title":"Classification of Diseases and Injuries--9th Edition Clinical Modification","year":"2009"},{"key":"10.1016\/j.clinthera.2014.09.016_bib11","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.amjcard.2009.07.022","article-title":"Increasing prevalence of atrial fibrillation and flutter in the United States","volume":"4","author":"Naccarelli","year":"2009","journal-title":"Am J Cardiology"},{"key":"10.1016\/j.clinthera.2014.09.016_bib12","first-page":"847","article-title":"Cost of atrial fibrillation in United States managed care organizations","volume":"26","author":"Kim","year":"2009","journal-title":"Advanced Therapeutics"},{"key":"10.1016\/j.clinthera.2014.09.016_bib13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.clinthera.2013.06.005","article-title":"Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population","volume":"35","author":"Deitelzweig","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.09.016_bib14","doi-asserted-by":"crossref","unstructured":"European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the Management of Atrial Fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.","DOI":"10.1093\/eurheartj\/ehq278"},{"issue":"603","key":"10.1016\/j.clinthera.2014.09.016_bib15","first-page":"603","article-title":"Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation","volume":"125","author":"Mason","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2014.09.016_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.09.016_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.09.016_bib18","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1093\/eurheartj\/ehp384","article-title":"The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin","volume":"30","author":"Camm","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.09.016_bib19","series-title":"FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC)","year":"2012"},{"key":"10.1016\/j.clinthera.2014.09.016_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AR Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.09.016_bib21","unstructured":"National Cardiovascular Data Registry. Pinnacle Registry For Coronary Artery Disease, Hypertension, Heart Failure, and Atrial Fibrillation in the Outpatient Setting. www.pinnacleregistry.org\/Pinnacle\/Libraries\/PINNACLE_Documents\/PINNACLE-AF_press_release_Aug_14_2012.sflb.ashx. Accessed Accessed July 4, 2014."},{"issue":"Supp 2l","key":"10.1016\/j.clinthera.2014.09.016_bib22","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2014.09.016_bib23","series-title":"Cost effectiveness of a new oral anticoagulation drug for stroke prevention in AF patients - A decision analysis of dabigatran: Medical Market Access Thesis","author":"Andersen","year":"2012"},{"key":"10.1016\/j.clinthera.2014.09.016_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","article-title":"Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation","volume":"16","author":"Coyle","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2014.09.016_bib25","doi-asserted-by":"crossref","first-page":"e62183","DOI":"10.1371\/journal.pone.0062183","article-title":"Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models","volume":"8","author":"Limone","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2014.09.016_bib26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.111.060061","article-title":"Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation","volume":"126","author":"Lane","year":"2012","journal-title":"Circulation"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T04:20:30Z","timestamp":1538108430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814006080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0149291814006080"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.09.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}